Glaukos (GKOS) closed at $181.43 on October 28, 2026, up 0.1% from the previous close, on volume of 1,513,062 shares (30-day average 968,438).
Data as of October 28, 2026.
Glaukos jumps after Q3 delivered 58% sales growth and a $1 billion 2027 revenue target
Market Chameleon (Thu, 29-Oct 6:27 AM ET)
Needham Sticks to Its Buy Rating for Glaukos (GKOS)
TipRanks (Thu, 29-Oct 8:10 AM ET)
TipRanks (Thu, 29-Oct 8:03 AM ET)
Piper Sandler Remains a Buy on Glaukos (GKOS)
TipRanks (Thu, 29-Oct 7:29 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Thu, 29-Oct 7:04 AM ET)
Glaukos Non-GAAP EPS of -$0.16 misses by $0.07, revenue of $211.03M beats by $42.97M
Seeking Alpha News (Wed, 28-Oct 4:44 PM ET)
Glaukos Delivers Record Q3 Results and Raises Guidance
TipRanks (Wed, 28-Oct 4:37 PM ET)
Glaukos Announces Third Quarter 2026 Financial Results
Business Wire (Wed, 28-Oct 4:05 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 28-Oct 10:00 AM ET)
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glaukos trades on the NYSE stock market under the symbol GKOS.
As of October 29, 2026, GKOS stock price climbed to $230.11 with 1,619,487 million shares trading.
GKOS has a beta of 0.19, meaning it tends to be less sensitive to market movements. GKOS has a correlation of 0.00 to the broad based SPY ETF.
GKOS has a market cap of $13.57 billion. This is considered a Large Cap stock.
Last quarter Glaukos reported $211 million in Revenue and $.47 earnings per share. This beat revenue expectation by $43 million and exceeded earnings estimates by $.57.
In the last 3 years, GKOS traded as high as $233.65 and as low as $59.22.
The top ETF exchange traded funds that GKOS belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
GKOS has outperformed the market in the last year with a price return of +195.8% while the SPY ETF gained +13.1%. GKOS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +52.1% and +37.1%, respectively, while the SPY returned +4.1% and 0.0%, respectively.
GKOS support price is $176.19 and resistance is $186.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GKOS shares will trade within this expected range on the day.
